SCHEMBL25815

SCHEMBL25815

CCCCCCCCCCCCCCCCC(O)(CCCCCCCCCCCCCCCC)C(O)CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
FDPS P14324 8/20 0.41
GGPS1 O95749 5/20 0.41
CYP2D6 P10635 2/20 0.39
SPHK1 Q9NYA1 1/20 0.39
GMNN O75496 1/20 0.39
POLB P06746 1/20 0.39
THPO P40225 1/20 0.39
MTOR P42345 1/20 0.39
BLM P54132 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
CETP P11597 1/20 0.39
HTT P42858 1/20 0.39
UBE2N P61088 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28434703 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL18863212 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL1890334 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL5820256 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL142854 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL2226505 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL5963212 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL139952 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL136611 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1
SCHEMBL29064953 1.00 LMNA (0.41) LMNAFDPSGGPS1CYP2D6SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 10638 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3419665-B1 TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 BRIGHAM & WOMENS HOSPITAL INC (US) 2024-10-30 EP claimed
US-20240229029-A9 COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-07-11 US claimed
US-20240141348-A1 ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-02 US claimed
US-20240132889-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-25 US claimed
US-20200016264-A1 NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT CUREVAC AG (DE) 2020-01-16 US claimed
US-10441653-B2 Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant CUREVAC AG (DE) 2019-10-15 US claimed
US-10260071-B2 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity COLEY PHARMACEUTICAL GMBH (DE) 2019-04-16 US claimed
US-20160348115-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity PFIZER INC. 2016-12-01 US claimed
EP-2078080-B1 CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY COLEY PHARM GMBH (DE) 2015-06-17 EP claimed
US-20140163213-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity COLEY PHARMACEUTICAL GMBH (DE) 2014-06-12 US claimed
US-20100166780-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity PFIZER INC 2010-07-01 US claimed
US-20090324584-A1 Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant CUREVAC GMBH (DE) 2009-12-31 US claimed
EP-2078080-A2 CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY Coley Pharmaceuticals GmbH (DE) 2009-07-15 EP claimed
EP-2046954-A2 NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT Curevac GmbH (DE) 2009-04-15 EP claimed
WO-2009018332-A1 SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND ALNYLAM PHARMACEUTICALS, INC. (US) 2009-02-05 WO claimed
WO-2008068638-A2 CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY COLEY PHARMACEUTICAL GMBH (DE) 2008-06-12 WO claimed
WO-2008014979-A2 NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT CUREVAC GMBH (DE) 2008-02-07 WO claimed
US-20070280929-A1 ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID CUREVAC GMBH (DE) 2007-12-06 US claimed
WO-2007095976-A2 ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID CUREVAC GMBH (DE) 2007-08-30 WO claimed
US-20060115461-A1 Apparatus and system having dry gene silencing compositions DHARMACON, INC. 2006-06-01 US claimed